Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund - IDCW - Direct Plan

Other Plans and Options
  • (-1.45%)Nav, as on 25-04-2025

  • Previous Nav

  • Net Change on 25-04-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to adopt passive investment strategy. The fund will invest in stocks comprising in the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
MSCI India Domestic & World Healthcare 45 Index N/A N/A N/A N/A N/A N/A
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
Axis Nifty 100 Index Fund - Direct Plan - IDCW Oct 18, 2019 6.28 13.40 22.22 0.21 1,715.36
Sundaram Nifty 100 Equal Weight Fund (Formerly Known as Principal Nifty 100 Equal Weight Fund)- Direct Plan - Income Distribution CUM Capital Withdrawal Option Jan 01, 2013 3.33 15.52 25.08 0.52 98.89

Fund Holdings as on 31-March-2025

  • Sun Pharmaceutical Industries Ltd.

  • Max Healthcare Institute Ltd.

  • Cipla Ltd.

  • ELI LILLY & CO

  • Dr. Reddy's Laboratories Ltd.

  • Divi's Laboratories Ltd.

  • Apollo Hospitals Enterprise Ltd.

  • Lupin Ltd.

  • JOHNSON & JOHNSON

  • ABBVIE INC

  • Torrent Pharmaceuticals Ltd.

  • Fortis Healthcare Ltd.

  • Aurobindo Pharma Ltd.

  • Mankind Pharma Ltd.

  • Novo Nordisk A/S

  • MERCK & CO.INC

  • ABBOTT LABORATORIES

  • NOVARTIS AG

  • Zydus Lifesciences Ltd.

  • Laurus Labs Ltd.

  • Glenmark Pharmaceuticals Ltd.

  • Alkem Laboratories Ltd.

  • IPCA Laboratories Ltd.

  • THERMO FISHER SCIENTIFIC INC

  • INTUITIVE SURGICAL INC

  • AMGEN INC

  • Biocon Ltd.

  • DANAHER CORP

  • GILEAD SCIENCES INC

  • STRYKER CORP

  • VERTEX PHARMACEUTICALS INC

  • Piramal Pharma Ltd.

  • Syngene International Ltd.

  • MEDTRONIC PLC

  • Suven Pharmaceuticals Ltd.

  • GlaxoSmithKline Pharmaceuticals Ltd.

  • Ajanta Pharma Ltd.

  • Narayana Hrudayalaya ltd.

  • Gland Pharma Ltd.

  • Global Health Ltd.

  • Regeneron Pharmaceuticals Inc

  • BECTON DICKINSON AND CO

  • Net Receivables/(Payables)

  • AGILENT TECHNOLOGIES INC

  • IQVIA HOLDINGS INC

  • ILLUMINA INC

  • Clearing Corporation of India Ltd.

  • Accrued Interest

View More

  • Pharmaceuticals & Drugs

  • Miscellaneous

  • Hospital & Healthcare Services

  • Business Support

View More

Fund Manager

  • Cash

  • Equity

View More

About Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund

Scheme Analysis

Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is a Index Funds - Other fund and belongs to Edelweiss Mutual Fund. It was launched on 26-Oct-2020 and currently has an AUM of ₹159.77 crore. Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is benchmarked against MSCI India Domestic & World Healthcare 45 Index as primary index and NIFTY 50 - TRI as secondary index.

The NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund ended down ₹-0.29(-1.45%)yesterday to ₹19.4041.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Ltd., and

The Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund is managed by Bhavesh Jain and Amit Vora.

Fund House Contact

Edelweiss House Off. C.S.T Road, Kalina, Mumbai - 400 098

(022) 40933400
(022) 40933401